Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

被引：0
|
作者：
Fang, W. F. [1 ]
Bu, Q. [2 ]
Wang, Q. M. [3 ]
Zhao, W. H. [4 ]
Wang, L. P. [5 ]
Dong, X. R. [6 ]
Chen, P. F. [7 ]
Wen, Z. B. [8 ]
Jia, J. [9 ]
Jiang, G. M. [9 ]
Zhang, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[5] Baotou Canc Hosp, Baotou, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[7] Zhuji Peoples Hosp, Zhuji, Peoples R China
[8] Peoples Hosp Gaozhou, Gaozhou, Peoples R China
[9] Dongguan Peoples Hosp, Dongguan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; high-dose; uncommon EGFR mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-07
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
    Fang, W.
    Bu, Q.
    Wang, Q.
    Zhao, W.
    Wang, L.
    Dong, X.
    Chen, P.
    Wen, Z.
    Jia, J.
    Jiang, G.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1588
  • [2] Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations
    Wu, L.
    Pu, X.
    Zhou, Y.
    Kong, Y.
    Chen, B.
    Yang, A.
    Li, J.
    Li, K.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1695 - S1695
  • [3] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
    Pu, Xingxiang
    Zhou, Yu
    Kong, Yi
    Chen, Bolin
    Yang, Aifang
    Li, Jia
    Li, Kang
    Xu, Yan
    Wu, Lin
    BMC CANCER, 2023, 23 (01)
  • [4] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
    Xingxiang Pu
    Yu Zhou
    Yi Kong
    Bolin Chen
    Aifang Yang
    Jia Li
    Kang Li
    Yan Xu
    Lin Wu
    BMC Cancer, 23
  • [5] Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Minemura, H.
    Sugiyama, T.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Minato, K.
    Kaburagi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S943 - S943
  • [6] A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations
    Wu, Fengying
    Zhou, Fei
    Zhao, Fuyou
    Zhang, Wei
    Wang, Lei
    Yu, Jia
    Xiong, Anweng
    Zhao, Jing
    Li, Wei
    Gao, Guanghui
    He, Yayi
    Bo, Bing
    Meng, Shuyan
    Han, Baohui
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Efficacy of first-generation EGFR-TKIs on patients with NSCLC harboring EGFR uncommon mutations: a pooled analysis
    Zhang, Y.
    Tang, S.
    Zhang, J.
    He, Q.
    He, J.
    Liang, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
    Passaro, Antonio
    Prelaj, Arsela
    Bonanno, Laura
    Tiseo, Marcello
    Tuzi, Alessandro
    Proto, Claudia
    Chiari, Rita
    Rocco, Danilo
    Genova, Carlo
    Sini, Claudio
    Cortinovis, Diego
    Pilotto, Sara
    Landi, Lorenza
    Bennati, Chiara
    Camerini, Andrea
    Toschi, Luca
    Putzu, Carlo
    Cerea, Giulio
    Spitaleri, Gianluca
    Cappuzzo, Federico
    de Marinis, Filippo
    CLINICAL LUNG CANCER, 2019, 20 (02) : E186 - E194
  • [9] Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area
    Zhang, J. Q.
    Feng, J. G.
    Liu, T.
    Zhang, X.
    Chen, X. B.
    Li, S. Y.
    Yuan, B.
    Xing, X. Q.
    Chai, Y. L.
    Jin, Z. X.
    Liang, Y. X.
    Xiao, Y.
    Li, M. H.
    Liu, L.
    Fang, L. Z.
    Shu, J. K.
    Zhang, J. Q.
    Jia, M.
    Li, Z. K.
    Li, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S673 - S673
  • [10] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
12345